Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	09/880,097
Filing Date	June 14, 2001
First Named Inventor	Anton WELLSTEIN
Art Unit	1647
Examiner Name	C. Nichols
Attorney Docket Number	544582000200

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
DK	1.	US-6,696,548-B2	02-24-2004	Morris et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
DK	2.	WO-01/96394-A2, A3	12-20-2001	Georgetown University Medical Center		

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK	3.	Albertoni, M. et al. (January 22, 1998). "Genetic Instability Leads to Loss of Both p53 Alleles in a Human Glioblastoma," *Oncogene* 16(3):321-326.	
DK	4.	Bashkin, P. et al. (February 21, 1989). "Basic Fibroblast Growth Factor Binds to Subendothelial Extracellular Matrix and Is Released by Heparitinase and Heparin-Like Molecules," *Biochemistry* 28(4):1737-1743.	
DK	5.	Basilico, C. et al. (1992). "The FGF Family of Growth Factors and Oncogenes," *In* Advances in Cancer Research Academic Press, Inc.: San Diego, CA 59:115-165.	
DK	6.	Bowers, D.C. et al. (August 1, 2000). "Scatter Factor/Hepatocyte Growth Factor Protects Against Cytotoxic Death in Human Glioblastoma via Phosphatidylinositol 3-Kinase- and AKT-dependent Pathways," *Cancer Res.* 60(15):4277-4283.	
DK	7.	Buczek-Thomas, J.A. et al. (1999). "Elastase-Mediated Release of Heparan Sulfate Proteoglycans from Pulmonary Fibroblast Cultures. A Mechanism for Basic Fibroblast Growth Factor (bFGF) Release and Attenuation of bFGF Binding Following Elastase-Induced Injury," *J. Biol. Chem.* 274:25167-25172.	
DK	8.	Chauhan, A.K. et al. (January 1993). "Pleiotrophin Transforms NIH 3T3 Cells and Induces Tumors in Nude Mice," *Proc. Natl. Acad. Sci. USA* 90:679-682.	
DK	9.	Choudhuri, R. et al. (May 1, 1997). "An Angiogenic Role for the Neurokines Midkine and Pleiotrophin in Tumorigenesis," *Cancer Res.* 57(9):1814-1819.	
DK	10.	Czubayko, F. et al. (August 19, 1994). "Ribozyme-Targeting Elucidates a Direct Role of Pleiotrophin in Tumor Growth," *J. Biol. Chem.* 269(33):21358-21363.	
DK	11.	Czubayko, F. et al. (November 11, 1994). "Tumor Growth and Angiogenesis Induced by a Secreted Binding Protein for Fibroblast Growth Factors," *J. Biol. Chem.* 269(45):28243-28248.	
DK	12.	Czubayko, F. et al. (December 1996). "Melanoma Angiogenesis and Metastasis Modulated by Ribozyme Targeting of the Secreted Growth Factor Pleiotrophin," *Proc. Natl. Acad. Sci. USA* 93:14753-14758.	
DK	13.	Czubayko, F. et al. (1997). "Adenovirus-Mediated Transduction of Ribozymes Abrogates HER-2/neu and Pleiotrophin Expression and Inhibits Tumor Cell Proliferation," *Gene Therapy* 4:943-949.	

Examiner Signature		Date Considered	5/18/05

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	2	of	3

Complete if Known	
Application Number	09/880,097
Filing Date	June 14, 2001
First Named Inventor	Anton WELLSTEIN
Art Unit	1647
Examiner Name	C. Nichols
Attorney Docket Number	544582000200

DK	14.	Czubayko, F. et al. (October 1997). "A Secreted FGF-Binding Protein Can Serve as the Angiogenic Switch in Human Cancer," *Nat. Med.* 3(10):1137-1140.	
DK	15.	Dove, A. (March 1999). "Proteomics: Translating Genomics into Products?" *Nat. Biotechnol.* 17:233-236.	
DK	16.	Fang, W. et al. (December 25, 1992). "Pleiotrophin Stimulates Fibroblasts and Endothelial and Epithelial Cells and Is Expressed in Human Cancer," *J. Biol. Chem.* 267(36):25889-25897.	
DK	17.	Furnari, F.B. et al. (November 1997). "Growth Suppression of Glioma Cells by PTEN Requires a Functional Phosphatase Catalytic Domain," *Proc. Natl. Acad. Sci. USA* 94:12479-12484.	
DK	18.	GenBank Accession No. U66559, created on February 24, 1997, located at <http://www.ncbi.nlm.nih.gov> last visited on March 3, 2005, three pages.	
DK	19.	Hanahan, D. et al. (January 7, 2000). "The Hallmarks of Cancer," *Cell* 100:57-70.	
DK	20.	Holland, E.C. (June 6, 2000). "Glioblastoma Multiforme: The Terminator," *Proc. Natl. Acad. Sci. USA* 97(12):6242-6244.	
DK	21.	Holland, E.C. et al. (May 2000). ""Combined Activation of Ras and Akt in Neural Progenitors Induces Glioblastoma Formation in Mice," *Nat. Genet.* 25:55-57.	
DK	22.	James, C.D. et al. (1996). "Molecular Genetics and Molecular Biology Advances in Brain Tumors," *Curr. Opin. Oncol.* 8:188-195.	
DK	23.	Khwaja, A. (September 2, 1999). "Akt is More Than Just a Bad Kinase," *Nature* 401:33-34.	
DK	24.	Klagsbrun, M. et al. (October 18, 1991). "A Dual Receptor System is Required for Basic Fibroblast Growth Factor Activity," *Cell* 67(2):229-231.	
DK	25.	Li, D-M. et al. (December 1998). "PTEN/MMAC1/TEP1 Suppresses the Tumorigenicity and Induces G1 Cell Cycle Arrest in Human Glioblastoma Cells," *Proc. Natl. Acad. Sci. USA* 95:15406-15411.	
DK	26.	Li, Y-S. et al. (December 21, 1990). "Cloning and Expression of a Developmentally Regulated Protein That Induces Mitogenic and Neurite Outgrowth Activity," *Science* 250:1690-1694.	
DK	27.	Maehama, T. et al. (April 1999). "PTEN: A Tumour Suppressor That Functions as a Phospholipid Phosphatase," *Trends Cell Biol.* 9:125-128.	
DK	28.	Merenmies, J. et al. (October 5, 1990). "Molecular Cloning of the 18-kDa Growth-Associated Protein of Developing Brain," *J. Biol. Chem.* 265(28):16721-16724.	
DK	29.	Morris, S.W. et al. (March 4, 1994). "Fusion of a Kinase Gene, *ALK*, to a Nucleolar Protein Gene, *NPM*, in Non-Hodgkin's Lymphoma," *Science* 263:1281-1284.	
DK	30.	Morris, S.W. et al. (January 20, 1995). "Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin's Lymphoma: Sequence Correction," - Erratum *Science* 267:316-317.	
DK	31.	Motegi, A. et al. (2004). "ALK Receptor Tyrosine Kinase Promotes Cell Growth and Neurite Outgrowth," *J. Cell Science* 117:3319-3329.	
DK	32.	Nishikawa, R. et al. (August 1994). "A Mutant Epidermal Growth Factor Receptor Common in Human Glioma Confers Enhanced Tumorigenicity," *Proc. Natl. Acad. Sci. USA* 91:7727-7731.	
DK	33.	Nistér, M. et al. (September 5, 1991). "Differential Expression of Platelet-Derived Growth Factor Receptors in Human Malignant Glioma Cell Lines," *J. Biol. Chem.* 266(25):16755-16763.	
DK	34.	Okada-Ban, M. (March 2000). "Fibroblast Growth Factor-2," *Int. J. Biochem. Cell Biol.* 32(3):263-267.	
DK	35.	O'Rourke, D.M. et al. (April 1997). "Trans Receptor Inhibition of Human Glioblastoma Cells by erbB Family Ectodomains," *Proc. Natl. Acad. Sci. USA* 94:3250-3255.	
DK	36.	Plate, K.H. et al. (October 29, 1992). "Vascular Endothelial Growth Factor is a Potential Tumour Angiogenesis Factor in Human Gliomas *in vivo*," *Nature* 359:845-848.	
DK	37.	Powers, C.J. et al. (2000). "Fibroblast Growth Factors, Their Receptors and Signaling," *Endocr. Relat. Cancer* 7(3):165-197.	
DK	38.	Schlessinger, J. (October 13, 2000). "Cell Signaling by Receptor Tyrosine Kinases," *Cell* 103:211-225.	

Examiner Signature		Date Considered	5/18/05

pa-961888

ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	3

Complete if Known	
Application Number	09/880,097
Filing Date	June 14, 2001
First Named Inventor	Anton WELLSTEIN
Art Unit	1647
Examiner Name	C. Nichols
Attorney Docket Number	544582000200

DK	39.	Schulte, A.M. et al. (December 1996). "Human Trophoblast and Choriocarcinoma Expression of the Growth Factor Pleiotrophin Attributable to Germ-Line Insertion of an Endogenous Retrovirus," *Proc. Natl. Acad. Sci. USA* 93:14759-14764.	
DK	40.	Schulte, A.M. et al. (1997). "Pleiotrophin and Related Molecules" Chapter 21 *In* Tumor Angiogenesis Bicknell, R. et al. eds. Oxford University Press: Oxford, UK 1:273-289.	
DK	41.	Schulte, A.M. et al. (July 1998). "Structure and Phylogenetic Analysis of an Endogenous Retrovirus Inserted into the Human Growth Factor Gene Pleiotrophin," *J. Virol.* 72(7):6065-6072.	
DK	42.	Singer, H.S. et al. (1999). "Mitogenesis in Glioblastoma Multiforme Cell Lines: A Role For NGF and its TrkA Receptors," *J. Neuro-oncol.* 45(1):1-8.	
DK	43.	Souttou, B. et al. (August 1, 1997). "Signal Transduction Pathways Involved in the Mitogenic Activity of Pleiotrophin. Implication of Mitogen-Activated Protein Kinase and Phosphoinositide 3-Kinase Pathways," *J. Biol. Chem.* 272(31):19588-19593.	
DK	44.	Souttou, B. et al. (October 7, 1998). "Relationship Between Serum Concentrations of the Growth Factor Pleiotrophin and Pleiotrophin-Positive Tumors," *J. Natl. Cancer Inst.* 90(19):1468-1473.	
DK	45.	Stoica, G.E. et al. (May 18, 2001). "Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin," *J. Biol. Chem.* 276(20):16772-16779.	
DK	46.	Wang, S.I. et al. (October 1, 1997). "Somatic Mutations of *PTEN* in Glioblastoma Multiforme," *Cancer Res.* 57:4183-1486.	
DK	47.	Weber, D. et al. (March 1999). "Pleiotrophin (PTN) Serves as an Essential Growth Factor in Pancreatic Cancer," *Proceedings of the 90th Annual Meeting of the American Association for Cancer Research* (April 10 -14, 1999) Philadelphia, PA, 40:732, Abstract No. 4834.	
DK	48.	Wellstein, A. et al. (February 5, 1992). "A Heparin-Binding Growth Factor Secreted From Breast Cancer Cells Homologous to a Developmentally Regulated Cytokine," *J. Biol. Chem.* 267(4):2582-2587.	
DK	49.	Wellstein, A. et al. (1999). "Ribozyme Targeting of Angiogenic Molecules" Chapter 25 *In* Antiangiogenic Agents in Cancer Therapy Teicher, B.A. ed. Humana Press, Inc.: Totowa, NJ. pp. 423-441.	
DK	50.	Wen, D. et al. (May 1, 1992). "Neu Differentiation Factor: A Transmembrane Glycoprotein Containing an EGF Domain and an Immunoglobulin Homology Unit," *Cell* 69:559-572.	
DK	51.	Wen, S. et al. (April 10, 2001). "PTEN Controls Tumor-Induced Angiogenesis," *Proc. Natl. Acad. Sci. USA* 98(8):4622-4627.	
DK	52.	Wu, D. et al. (September 5, 1991). "Characterization and Molecular Cloning of a Putative Binding Protein for Heparin-Binding Growth Factors," *J. Biol. Chem.* 266(25):16778-16785.	
DK	53.	Yeh, H-J. et al. (May 15, 1998). "Upregulation of Pleiotrophin Gene Expression in Developing Microvasculature, Macrophages, and Astrocytes after Acute Ischemic Brain Injury," *J. Neurosci.* 18(10):3699-3707.	
DK	54.	Zhang, N. et al. (July 4, 1997). "Human Breast Cancer Growth Inhibited *in Vivo* by a Dominant Negative Pleiotrophin Mutant," *J. Biol. Chem.* 272(27):16733-16736.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	5/18/05

pa-961888

ALTERNATIVE TO PTO/SB/08a/b (06-03)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1

Complete If Known	
Application Number	09/880,097
Filing Date	June 14, 2001
First Named Inventor	Anton WELLSTEIN
Art Unit	1647
Examiner Name	C. Nichols
Attorney Docket Number	544582000200

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
DK	1.	European Examination Report for European Patent Application No. 01944466.0, mailed on March 22, 2005, 4 pages.	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	5/18/05

pa- 974952